This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wide Field Looking to Trim Weight

Over the summer, Minneapolis-based Medtronic (MDT - Get Report), the largest maker of medical devices for the heart, acquired a small company called Transneuronix for its Transcend stomach stimulator . The device is built to distend the stomach and convince the brain that it's full. The Transcend is currently in trials and could be on the market as early as the first half of next year.

Another big heart device company, St. Jude Medical (STJ - Get Report), plans to buy Advanced Neuromodulation Systems (ANSI), whose offerings include an experimental device to treat obesity. The product uses electrical stimulation, but Advanced wouldn't comment on the device or the progress of its development. As of Wednesday, St. Jude already owned 89% of the company.

Even with the forays into the weight-loss field, Medtronic and St. Jude have mainly been focused on heart-failure devices, which obviously treat a condition that carries a more immediate risk of death.

"If you need a defibrillator, you need it today," says John Putnam of Stanford Financial Group. "It's not like obesity, where you need to lose some weight, but over a period of time."

Should the experimental gastric stimulators prove effective, Inamed's Lap-Band market would be an obvious target for both Medtronic and St. Jude, according to Jason Wittes of biotech research firm Leerink Swann. Implanting a gastric stimulator, similar to putting a pacemaker in a patient, would be less invasive than inserting the band, he says. Additionally, he says the stimulation products might even be used in a broader set of patients.

Not Just Skin Deep

While about one-third of the U.S. population is considered obese, about 5% of the population -- a small number of whom have the band implanted -- is morbidly obese, or more than 100 pounds overweight, according to the National Institutes of Health.

Inamed's gastric band itself could soon be the property of another firm, as both Medicis (MRX) and Allergan (AGN) are bidding for the company .
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMDC $0.00 0.00%
MDT $79.16 -0.78%
MYGN $36.01 -3.10%
STJ $76.21 -2.00%
AAPL $93.75 -1.10%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs